Iran aims to launch human trials of Parkinson’s brain stimulation technology by 2027
Iran aims to launch human trials of Parkinson’s brain stimulation technology by 2027
Publish Date: 2026-06-19 06:55:00
Source Domain: tvbrics.com
Iran has reported significant progress in the development of deep brain stimulation (DBS) technology, an advanced neuromodulation method used to treat Parkinson’s disease and other complex neurological disorders. Researchers expect the project to enter human clinical trials by 2027 if current testing phases are successfully completed, as reported by
Mehr News Agency, a TV BRICS partner.
Deep brain stimulation is considered one of the most sophisticated treatments in modern neuroscience. The technique involves implanting electrodes into specific regions of the brain to deliver controlled electrical impulses that regulate abnormal neural activity. Unlike older surgical approaches that permanently alter brain tissue, DBS modulates neural circuits without destroying them, allowing physicians to adjust stimulation settings according to each patient’s condition.
The technology has been widely used internationally to help manage symptoms associated with Parkinson’s disease, severe tremors, dystonia, treatment-resistant epilepsy and certain psychiatric disorders. In Parkinson’s patients, DBS can reduce tremors, muscle rigidity, slowed movement and motor fluctuations, while in epilepsy patients it may help decrease the frequency and severity of seizures.
According to officials overseeing the programme, the Iranian project has been under development for approximately a decade and has recently reached a key milestone.
Health experts estimate that around 2,000 patients in Iran each year could benefit from deep brain stimulation therapy. The technology is considered particularly important for individuals with Parkinson’s disease, treatment-resistant epilepsy, severe depression and certain movement disorders that do not respond adequately to conventional therapies.
Officials expressed optimism that, following the successful completion of the current preclinical phase and subsequent safety…
